Company News
- Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
Apr 27, 2021, 9:05 AM EDT - Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol® Cyclo™ in Alzheimer’s Disease
Apr 20, 2021, 9:25 AM EDT - Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Disease Niemann-Pick Type C1 (NPC1)
Mar 25, 2021, 8:35 AM EDT - Cyclo Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
Mar 15, 2021, 8:05 AM EDT - Cyclo Therapeutics to Participate in Inaugural Emerging Growth Virtual Conference
Mar 12, 2021, 8:05 AM EST - Cyclo Therapeutics Appoints Russ Belden as Acting Chief Commercial Officer
Mar 10, 2021, 8:35 AM EST - Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol® Cyclo™
Mar 9, 2021, 9:05 AM EST - Cyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Mar 4, 2021, 9:10 AM EST - Cyclo Therapeutics Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical Officer
Mar 1, 2021, 9:05 AM EST - Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families
Feb 22, 2021, 9:00 AM EST - Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021
Feb 9, 2021, 8:05 AM EST - Cyclo Therapeutics to Present on Its Clinical and Drug Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021
Jan 26, 2021, 8:00 AM EST - Cyclo Therapeutics Announces Positive Efficacy Data from Extension Protocol with Trappsol® Cyclo™ in Patients with Niemann-Pick Disease Type C
Jan 5, 2021, 8:00 AM EST - Cyclo Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares of Common Stock in Connection with its Underwritten Public Offering
Dec 22, 2020, 2:30 PM EST - Cyclo Therapeutics Announces Pricing of $12.5 Million Public Offering
Dec 9, 2020, 12:52 PM EST - Cyclo Therapeutics Announces Two Presentations at WORLDSymposium2021
Nov 19, 2020, 8:00 AM EST - Cyclo Therapeutics Phase 3 Pivotal Program Can Begin Enrollment Per US FDA
Oct 21, 2020, 10:53 AM EDT - Cyclo Therapeutics to Present at 2020 Annual Conference for NPC Patients, Families, and Health Professionals in the United Kingdom
Sep 21, 2020, 8:00 AM EDT - Cyclo Therapeutics Inc. Announces Additional Efficacy Data from its Ongoing Phase I/II Trial using Trappsol® CycloTM Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1)
Sep 8, 2020, 8:38 AM EDT - Cyclo Therapeutics Closes $2.8 Million Private Placement Led by Novit LP With $1.0 Million
Aug 27, 2020, 8:00 AM EDT - Cyclo Therapeutics Announces Presentations on Phase I and Phase I/II Trials using Trappsol® Cyclo™ Intravenously to Treat Patients with Niemann-Pick Disease Type C1 at National Niemann Pick Disease Foundation Family Support and Medical Conference
Jul 9, 2020, 11:20 AM EDT - Cyclo Therapeutics Reports on Eighteen Month Expanded Access Program in Single Alzheimer’s Patient
Jun 17, 2020, 8:00 AM EDT - Cyclo Therapeutics’ Clinical Data Webinar Recording Available on Company Website
May 26, 2020, 8:00 AM EDT - Cyclo Therapeutics Inc. Announces Positive Top Line Results from Phase I Trial and Interim Analysis of Phase I/II Trial using Trappsol® Cyclo™ Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1)
May 20, 2020, 8:00 AM EDT - Cyclo Therapeutics to Hold Call for Patients and Investors Wednesday, May 20 at 4:30 pm EDT
May 19, 2020, 8:00 AM EDT - Cyclo Therapeutics Announces Positive Feedback from European Medicines Agency on its Pivotal Trial Design for Trappsol® Cyclo™ for Niemann-Pick Disease Type C1
May 18, 2020, 8:00 AM EDT - Cyclo Therapeutics Reports Publication of International Patent Application for Treatment of Alzheimer’s Disease
May 14, 2020, 8:00 AM EDT - Cyclo Therapeutics Closes $2.0 Million Private Placement
Apr 27, 2020, 8:00 AM EDT - Cyclo Therapeutics Inc. Announces Positive Safety Profile of Its Drug Trappsol® Cyclo™ in the Treatment of Niemann Pick Disease Type C
Mar 23, 2020, 8:05 AM EDT - Cyclo Therapeutics Announces Positive Feedback from FDA on its Pivotal Trial Design for Trappsol® Cyclo™ for Niemann-Pick Disease Type C1
Mar 2, 2020, 8:00 AM EST - Cyclo Therapeutics Announces Completion of Enrollment in its Extension Protocol to the Phase I Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Feb 26, 2020, 8:00 AM EST - Cyclo Therapeutics Announces Completion of Enrollment in its Phase I/II Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Feb 20, 2020, 8:00 AM EST - Last Patient Last Visit in Cyclo Therapeutics’ Phase I Trial in Niemann-Pick Type C
Feb 11, 2020, 8:13 AM EST - Cyclo Therapeutics, Inc. Poster Presentation of Clinical Trial Data on Niemann-Pick Type C Disease at the 16th Annual WORLDSymposium Now Available
Feb 5, 2020, 8:00 AM EST - Cyclo Therapeutics to Present at BIOTECH SHOWCASE™ 2020 in San Francisco
Jan 7, 2020, 8:00 AM EST - Cyclo Therapeutics Signs Master Services Agreement with Worldwide Clinical Trials
Dec 27, 2019, 8:00 AM EST - Cyclo Therapeutics Receives Buy Recommendation and $1.25 Price Target from ThinkEquity
Dec 18, 2019, 7:00 AM EST - Cyclo Therapeutics, Inc. to Present Clinical Trial Data on Niemann-Pick type C Disease at the 16th Annual WORLDSymposium
Dec 16, 2019, 8:00 AM EST - Cyclo Therapeutics’ Chief Scientific Officer Appointed to President’s Council of Advisors on Science and Technology
Dec 10, 2019, 5:10 AM EST - Cyclo Therapeutics Signs Agreement with Worldwide Clinical Trials to Conduct Pivotal Trial in Niemann-Pick Disease Type C
Nov 8, 2019, 8:00 AM EST - Cyclo Therapeutics Announces Its Publication of the Most Extensive Set of Case Study Reports To-Date on Expanded Access Use of Hydroxypropyl Beta Cyclodextrin in Niemann-Pick Disease Type C
Oct 31, 2019, 8:00 AM EDT - Cyclo Therapeutics Signs Agreement with Worldwide Clinical Trials to Conduct Alzheimer’s Disease Clinical Trial
Oct 30, 2019, 8:00 AM EDT - Cyclo Therapeutics Prepares for Alzheimer’s Development Program After Success with First Patient
Oct 28, 2019, 7:00 AM EDT - Cyclo Therapeutics, Inc. Chief Scientific Officer, Sharon H. Hrynkow, Ph.D., Appointed to President’s Council on Science and Technology
Oct 23, 2019, 8:00 AM EDT - Cyclo Therapeutics Announces Completion of Enrollment in its Phase I Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Oct 22, 2019, 8:00 AM EDT - Cyclo Therapeutics Announces Its Support for The Firefly Fund’s Newborn Screening Program
Oct 18, 2019, 8:00 AM EDT - Cyclo Therapeutics, Inc. Announces Maurizio Scarpa, MD as EU Coordinating Investigator for the Company’s Pivotal Trial in Niemann-Pick Disease Type C
Oct 9, 2019, 8:00 AM EDT - Cyclo Therapeutics, Inc. – The New Name for CTD Holdings.
Oct 4, 2019, 8:00 AM EDT - CTD Holdings Receives Buy Recommendation from Frazier, Browne and Mayer's Strategic Allocator, a High Net-Worth Investor Journal
Oct 3, 2019, 9:15 AM EDT - CTD Holdings Announces New Collaboration with the Chattanooga Center for Neurologic Research to Advance Alzheimer’s Disease Study
Sep 27, 2019, 10:23 AM EDT - Why Did Board Insiders Recently Buy More Than 500,000 Shares of This Company's Stock?
Sep 17, 2019, 11:30 AM EDT - CTD Holdings Announces FDA Approval of US Expanded Access Treatment Program in Niemann-Pick Disease Type C
Sep 13, 2019, 8:00 AM EDT - CTD Holdings to Present at 2019 Annual Conference for NPC Patients, Families, and Health Professionals in the United Kingdom
Sep 11, 2019, 8:07 AM EDT - CTD Holdings Interview to Air on Bloomberg International on the RedChip Money Report
Sep 4, 2019, 11:46 AM EDT - CTD Holdings Holds Shareholders’ Meeting: All Proposals are Approved
Aug 27, 2019, 11:14 AM EDT - CTD Announces New Data Presented at Annual Gathering of Patients and Families Tackling Niemann-Pick Disease Type C
Aug 15, 2019, 8:00 AM EDT - CTD Holdings Announces Filing of Data From Expanded Access Program in Late Onset Alzheimer’s Disease in Support of Its Patent Application Filed In 2018
Aug 13, 2019, 8:00 AM EDT - CTD Announces Support and Participation at Annual Family Conference of National Niemann-Pick Disease Foundation
Jul 31, 2019, 9:28 AM EDT - CTD Holdings Scientific Advisory Board Endorses Alzheimer’s Disease as Next Indication for Company’s Trappsol® Cyclo™ Drug Development Program
Jul 18, 2019, 10:24 AM EDT - CTD Obtains Right of Reference to Alzheimer’s Disease Expanded Access Data
Jul 11, 2019, 11:05 AM EDT - CTD Appoints Head of Global Regulatory Affairs
Jul 8, 2019, 8:00 AM EDT - CTD Holdings Submits Application for Listing on NASDAQ
Jun 12, 2019, 12:53 PM EDT - CTD Announces Continuation of Expanded Access Program in Single Alzheimer's Patient
Jun 10, 2019, 8:00 AM EDT - CTD Holdings Closes $7.4 Million Private Placement
May 31, 2019, 12:35 PM EDT - CTD Holdings Announces $7.2 Million Private Placement
May 30, 2019, 9:20 AM EDT - CTD Announces Home-Based Dosing of First Patient in US Extension Protocol of Clinical Trial using Intravenous Administration of Trappsol (R) Cyclo (TM) for Niemann-Pick Disease Type C
May 23, 2019, 8:00 AM EDT - CTD Announces Participation and Support for Upcoming Gathering of Patient-Support Organizations for Niemann-Pick Disease type C
May 16, 2019, 8:00 AM EDT - CTD Announces New Expanded Access Program in the United Kingdom using Trappsol(R) Cyclo(TM) Intravenously for Niemann-Pick Disease type C
May 10, 2019, 8:25 AM EDT - CTD Announces New Expanded Access Program in Taiwan using Trappsol Cyclo for Niemann-Pick Disease type C
May 7, 2019, 8:00 AM EDT - CTD Holdings Announces M. Flint Beal, MD Joins Scientific Advisory Board
Apr 15, 2019, 8:00 AM EDT - CTD Holdings Announces Plan to Launch Clinical Trial of Trappsol (R) Cyclo (TM) in Alzheimer's Disease
Mar 14, 2019, 8:00 AM EDT - CTD Holdings to Present at Webinar for Patients and Families on Initial Clinical Trial Data
Mar 8, 2019, 8:00 AM EST - CTD Holdings Announces Grant to U.S. Non-Profit Organization to Support Patient Participation in Informational Meetings with Regulators
Feb 28, 2019, 10:00 AM EST - CTD Announces Appointment of Sharon H. Hrynkow, PhD as Chief Scientific Officer
Feb 15, 2019, 10:04 AM EST - CTD Reports Initial Data for Two Clinical Trials of Trappsol® Cyclo™ Provided Intravenously for Patients with Niemann-Pick Disease Type C
Feb 7, 2019, 8:00 AM EST - CTD Announces Partnership with United BioSource LLC (UBC) to support the Extension Protocol for its Phase I Clinical Trial in the United States
Jan 18, 2019, 8:00 AM EST - CTD Announces Presentation at Upcoming Conference on Lysosomal Storage Diseases
Jan 10, 2019, 8:00 AM EST - CTD Holdings’ Senior VP for Medical Affairs Appointed to Committee of the National Academies of Sciences, Engineering, and Medicine
Jan 8, 2019, 8:52 AM EST - CTD Holdings Closes $2.0 Million Private Placement
Dec 21, 2018, 8:00 AM EST - CTD Holdings to Present at WORLD Symposium on Lysosomal Storage Diseases
Dec 12, 2018, 8:00 AM EST - CTD Holdings to Present at Brains for Brain Conference on Lysosomal Storage Diseases
Dec 10, 2018, 9:11 AM EST - CTD Holdings Engages Torreya Capital as Strategic Advisor
Nov 13, 2018, 8:43 AM EST - CTD Announces Partnership with Synteract to support the Extension Protocol for its Phase I Clinical Trial in the United States
Nov 8, 2018, 3:07 PM EST - CTD Holdings Announces Filing of Patent Application for Use of Hydroxypropyl Beta Cyclodextrins in the Treatment of Alzheimer’s Disease
Oct 29, 2018, 6:49 PM EDT - CTD Holdings Posts Recording of its Webinar on US Clinical Trial
Oct 18, 2018, 4:31 PM EDT - CTD Holdings Announces Plans to Broaden its Expanded Access Program for Trappsol® Cyclo™
Oct 15, 2018, 8:00 AM EDT - CTD Holdings to Host Webinar on its Phase I Clinical Trial for Niemann-Pick Disease Type C
Oct 11, 2018, 12:57 PM EDT - CTD Holdings to Present at BioFlorida Conference with update on Clinical Program Using Cyclodextrins to treat diseases with Unmet Medical Needs
Oct 9, 2018, 12:03 PM EDT - CTD Holdings Establishes Second Clinical Trial Site for US Phase I Clinical Study of Trappsol® Cyclo™ for Treatment of Niemann-Pick Disease Type C
Oct 5, 2018, 8:00 AM EDT - CTD announces encouraging top-line data from two ongoing clinical trials of Trappsol® Cyclo™ administered intravenously in Niemann Pick Disease Type C (NPC)
Oct 3, 2018, 8:00 AM EDT - CTD Holdings to Present at UK Annual Conference for NPC Patients, Families, and Health Professionals
Sep 13, 2018, 10:56 AM EDT - CTD Holdings Discusses its Phase I Clinical Trial for Intravenous Use of Trappsol® Cyclo™ in Niemann-Pick Disease Type C
Aug 30, 2018, 12:11 PM EDT - CTD Holdings’ Trappsol® Cyclo™ Featured in Television Program on Niemann-Pick Disease Type C
Aug 23, 2018, 8:00 AM EDT - CTD Holdings Announces Expanded Access Protocol using Intravenous Trappsol® Cyclo™ for Alzheimer’s Disease
Aug 13, 2018, 8:00 AM EDT - CTD is working to establish a second clinical trial site at Morristown Medical Center, Atlantic Health System, Morristown, NJ
Aug 6, 2018, 8:00 AM EDT - CTD to Present at National Niemann-Pick Disease Foundation Annual Conference
Jun 27, 2018, 8:00 AM EDT - FDA Authorizes CTD to Proceed with Extension Protocol to US Phase I Trappsol(R) Cyclo(TM) Trial for Niemann-Pick Disease Type C
Apr 30, 2018, 8:00 AM EDT - CTD Holdings Closes $2.00 Million Private Placement
Apr 23, 2018, 8:00 AM EDT - CTD Holdings Finalizes Cooperative Agreement for Alzheimer's Disease Research Program
Apr 19, 2018, 8:00 AM EDT - CTD Holdings Conducts Initial Review of Safety Data for its Phase I and Phase I/II Trials of Trappsol(R) Cyclo(TM) to Treat Niemann-Pick Disease Type C
Mar 29, 2018, 1:45 PM EDT - Randall M. Toig, M.D. Joins CTD Holdings Board of Directors
Mar 20, 2018, 8:00 AM EDT - CTD Holdings Announces FDA Authorization to Proceed with Single Patient IND for Use of Trappsol(R) Cyclo(TM) to Treat Alzheimer's Disease
Mar 12, 2018, 9:04 AM EDT - CTD Holdings Initiates Research Program to Explore Cyclodextrin Therapy for Alzheimer's Disease
Jan 29, 2018, 8:00 AM EST - CTD Holdings' European Clinical Trial Adopted by National Institute for Health Research of England
Jan 16, 2018, 8:00 AM EST - CTD Holdings Receives Rare Pediatric Disease Designation for Trappsol(R) Cyclo(TM)
Dec 6, 2017, 8:00 AM EST - CTD Holdings Closes $1.5 Million Private Placement
Oct 18, 2017, 8:00 AM EDT - CTD Holdings Enrolls First Patient in US Phase I Clinical Trial of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Disease Type C
Sep 28, 2017, 8:00 AM EDT - CTD Holdings to Present at UK Annual Conference for NPC Patients, Families and Caregivers
Sep 22, 2017, 8:00 AM EDT - CTD Holdings Announces Approval of Clinical Trial Application to Conduct Phase I/II Clinical Study of Trappsol(R) Cyclo(TM) in Patients with Niemann-Pick Type C Disease in Israel
Sep 18, 2017, 8:00 AM EDT - CTD Holdings Announces First Patient Dosed in Phase I/II Clinical Trial to Evaluate Trappsol(R) Cyclo(TM) in Niemann-Pick Disease Type C
Jul 19, 2017, 8:00 AM EDT - CTD Holdings to Present at 25th Annual Family Conference of the National Niemann-Pick Disease Foundation
Jul 13, 2017, 12:31 PM EDT - CTD Holdings Ships Additional Trappsol(R) Cyclo(TM) to Brazil
Jun 27, 2017, 8:00 AM EDT - CTD Holdings Enrolls First Patient in European Phase I/II Clinical Trial of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Disease Type C
Jun 21, 2017, 8:00 AM EDT - CTD Holdings Announces Appointments of Two Patient Liaisons to Enhance Outreach to Niemann-Pick Disease Type C Families and Caregivers
Jun 14, 2017, 8:12 AM EDT - CTD Holdings to Host Webinar to Provide Update on Trappsol(R) Cyclo(TM) Drug Development Program for Treatment of Niemann-Pick Disease Type C
May 16, 2017, 8:26 AM EDT - CTD Holdings Corrects Mis-Statements about Its Product Made in On-Line Publication
Apr 19, 2017, 11:42 AM EDT - CTD Issues Open Letter to Niemann-Pick Disease Type C Community and CTD Stakeholders
Apr 10, 2017, 2:52 PM EDT - CTD Holdings Initiates Recruitment for U.S. Phase I Clinical Study of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Disease Type C
Mar 23, 2017, 8:00 AM EDT - CTD Holdings Initiates Recruitment for Phase I/II Clinical Study in Europe of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Disease Type C
Mar 21, 2017, 8:00 AM EDT - CTD Holdings Closes $2 Million Private Placement
Feb 23, 2017, 7:53 AM EST - CTD Holdings Presents Compassionate Use Data on Trappsol(R) Cyclo(TM) to Treat Niemann-Pick Disease Type C and Provides Update on Progress of U.S. and EU Clinical Trials at 13th Annual WORLDSymposium
Feb 16, 2017, 8:00 AM EST - CTD Holdings Receives FDA Fast Track Designation for Development of Trappsol(R) Cyclo(TM) to Treat Niemann-Pick Disease Type C
Jan 17, 2017, 8:00 AM EST - CTD Holdings Files Clinical Trial Application with Italian Drug Agency to Continue Advancing Trappsol(R) Cyclo(TM) Drug Development Program to Treat Niemann-Pick Disease Type C
Dec 21, 2016, 8:00 AM EST - CTD Holdings to Present at the WORLDSymposium on Compassionate Use of Cyclodextrins to Treat Niemann Pick Disease Type C and on Progress in US and EU Clinical Trials
Dec 15, 2016, 12:09 PM EST - CTD Holdings to Present at the 2016 BioFlorida Annual Conference on Use of Cyclodextrins to Treat Niemann Pick Disease Type C
Dec 8, 2016, 8:00 AM EST - CTD Holdings Announces Approval of Clinical Trial Application to Conduct Phase I/II Clinical Study of Trappsol(R) Cyclo(TM) in Patients with Niemann-Pick Type C Disease at Karolinska University Hospital
Nov 10, 2016, 8:00 AM EST - CTD Holdings Presents on Clinical Trials at Niemann-Pick UK Conferences
Sep 28, 2016, 7:00 AM EDT - CTD Holdings Announces MHRA Approval of Clinical Trial Application for Treatment of NPC With Trappsol(R) Cyclo(TM)
Sep 15, 2016, 7:00 AM EDT - CTD Holdings Files Clinical Trial Application With Swedish Medical Products Agency to Continue Advancing Its Drug Development Program
Sep 12, 2016, 7:00 AM EDT - CTD Holdings Announces FDA Acceptance of Investigational New Drug Application for Treatment of NPC With Trappsol(R) Cyclo(TM)
Sep 6, 2016, 7:00 AM EDT - CTD Holdings Meets With Parent Advocate Groups and Physicians
Aug 16, 2016, 11:14 AM EDT - CTD Holdings Files Investigational New Drug Application With US FDA to Further Advance Its Drug Development Program
Aug 8, 2016, 7:00 AM EDT - CTD Holdings Files Clinical Trial Application With U.K. Regulatory Agency to Advance Its Drug Development Program
Aug 1, 2016, 8:31 AM EDT - CTD Holdings to Present at Niemann-Pick UK Workshop and Family Conference
Jul 18, 2016, 9:37 AM EDT - CTD Senior VP to Advise University at Buffalo on Global Biomedical Science
Jul 7, 2016, 7:00 AM EDT - CTD Holdings Announces Joint Presentation With UCSF Benioff Children's Hospital Oakland on Patient Experience in Compassionate Treatment Program
Jun 28, 2016, 7:00 AM EDT - CTD Holdings Expands Family and Physicians Listening Circle on NPC
Jun 24, 2016, 11:40 AM EDT - CTD Holdings Lead Director Markus W. Sieger Named CEO of Polpharma
Jun 13, 2016, 7:00 AM EDT - CTD Holdings Closes on $2 Million Private Placement
Jun 7, 2016, 7:00 AM EDT - CTD Holdings to Present "Management of Niemann-Pick Type C With Intravenous Hydroxypropyl- b -Cyclodextrin" at Ara Parseghian Medical Research Foundation Annual Conference
May 3, 2016, 7:00 AM EDT - CTD Holdings' Clinical Program to Move Forward in the U.S.
Feb 29, 2016, 7:00 AM EST - Parent Advocates Join CTD Holdings Family and Physicians Listening Circle on NPC Treatment
Feb 18, 2016, 7:11 AM EST - CTD Holdings Enters Into Letter of Intent to Sell Fine Chemical Unit
Jan 13, 2016, 7:24 AM EST - CTD Holdings' Clinical Trial Design Receives Positive Responses From U.K.'s Medicines and Healthcare Products Regulatory Agency
Dec 14, 2015, 7:00 AM EST - Joseph J. Farnan, Jr. Joins CTD Holdings Board of Directors
Nov 4, 2015, 12:31 PM EST - CTD Holdings Names Dr. Rita Colwell and Dr. Sharon Hrynkow Co-Chairs of Scientific Advisory Board
Oct 26, 2015, 12:40 PM EDT - N. Scott Fine Named CEO of CTD Holdings
Sep 16, 2015, 3:00 AM EDT - CTD Holdings to Present at UK Annual Conference for NPC Patients, Families and Caregivers
Sep 3, 2015, 7:00 AM EDT - Scarsdale Equities Leads Private Investment in CTD Holdings
Aug 31, 2015, 7:00 AM EDT - CTD Holdings Sets Meeting With European Health Authority on Clinical Development Plans
Aug 24, 2015, 7:00 AM EDT - CTD Holdings Pledges $1 Million of Trappsol(R) Cyclo(TM) to Niemann-Pick Type C Patients
Aug 7, 2015, 7:00 AM EDT - Dr. Camilo Vieira and Pessoa Parents Join CTD Holdings Family and Physicians Listening Circle on NPC Treatment
Jul 28, 2015, 7:00 AM EDT - CTD Holdings Receives $1.3 Million Follow-On Investment Led by U.S. Pharmacia Investment Arm Novit L.P.
Jul 13, 2015, 7:00 AM EDT - Dr. Elin Haf Davies Withdraws From CTD Holdings' Family and Physicians Listening Circle on NPC Treatment
Jul 10, 2015, 9:15 AM EDT - CTD Holdings Ships Additional Trappsol(R) Cyclo(TM) to Brazil
Jun 30, 2015, 7:00 AM EDT - CTD Holdings Obtains US Orphan Drug Designation for Trappsol(R) Cyclo(TM)
Jun 24, 2015, 7:00 AM EDT - Dr. Elin Haf Davies Joins CTD Holdings' Family and Physicians Listening Circle on NPC Treatment
Jun 22, 2015, 7:00 AM EDT - Dr. Begona Arias Joins CTD Holdings' Family and Physicians Listening Circle on NPC Treatment
Jun 10, 2015, 7:00 AM EDT - CTD Holdings Announces Family and Physicians Listening Circle on NPC Treatment
Jun 8, 2015, 7:00 AM EDT - CTD Holdings Names Dr. Benny Liu, M.D. to Scientific Advisory Board
May 18, 2015, 7:00 AM EDT - CTD Holdings Names Professor James E.K. Hildreth to Scientific Advisory Board
May 4, 2015, 7:00 AM EDT - CTD Holdings Expands International Clinical Program Team
Apr 28, 2015, 7:00 AM EDT - Baltimore Sun Publishes Op-Ed by CTD Executive Chairman and Scientific Advisory Board Member
Apr 21, 2015, 7:00 AM EDT - CTD Holdings Obtains European Orphan Drug Designation for Trappsol(R) Cyclo(TM)
Apr 7, 2015, 7:00 AM EDT - CTD Holdings Amends Agreement With Medical Need Europe
Apr 2, 2015, 7:00 AM EDT - CTD Holdings Names Caroline Hastings, M.D., to Scientific Advisory Board
Mar 17, 2015, 7:00 AM EDT - CTD Holdings Selects Accenture to Lead Orphan Drug Clinical Program in Europe
Mar 13, 2015, 7:00 AM EDT - FDA Accepts CTD Holdings' Drug Master File for Second-Generation Orphan Drug
Jan 27, 2015, 6:00 AM EST - N. Scott Fine Named Board Chairman of Global Virus Network
Jan 8, 2015, 7:00 AM EST - CTD Holdings Names Dr. Sharon H. Hrynkow to Scientific Advisory Board
Nov 10, 2014, 7:00 AM EST - CTD Holdings Names New Board Chairman
Oct 1, 2014, 7:00 AM EDT - CTD Holdings Reports Progress in Orphan Drug Development and Acquires Equity Capital in Second Quarter
Aug 15, 2014, 8:00 AM EDT - CTD Holdings Closes $1.725 Million Private Placement
Jul 22, 2014, 10:16 AM EDT - CTD Holdings Names New Chief Executive
Jul 9, 2014, 8:36 AM EDT - CTD Holdings President Named Chairman of 18th International Cyclodextrin Symposium
Jun 5, 2014, 8:00 AM EDT - CTD Holdings Names N. Scott Fine Vice Chairman and Lead Director
May 22, 2014, 12:22 AM EDT - CTD Holdings Reports Strong Product Sales and Acquires Equity Capital in First Quarter
May 14, 2014, 3:01 PM EDT - CTD Holdings, Inc. Closes on Securities Purchase and Collaboration Agreement
Apr 16, 2014, 6:00 AM EDT - CTD Holdings Reports Record Revenues for 2013
Mar 11, 2014, 3:45 PM EDT - CTD Holdings, Inc. Closes on Private Placement
Feb 20, 2014, 12:00 AM EST - CTD Holdings, Inc. Announces Refinancing of Long Term Debt
Aug 8, 2013, 3:00 AM EDT - CTD Holdings, Inc. Reports Revenue of $442,000, Representing Growth of 73.7% for the First Quarter 2012
May 21, 2012, 7:45 AM EDT - CTD Holdings, Inc. Announces That Its Form 10-Q for the First Quarter 2012 Will be Delayed Due to Administrative Reasons
May 11, 2012, 7:31 AM EDT - CTD Holdings, Inc. - NanoSonic Products Division Signs Exclusive Distribution Agreement With Uno Healthcare
Mar 26, 2012, 7:50 AM EDT - CTD Holdings, Inc. Reports Record Revenues for Fiscal 2011
Mar 19, 2012, 8:10 AM EDT - CTD Holdings, Inc. - NanoSonic Products Division Signs Manufacturing Agreement With Florida Biologix
Feb 22, 2012, 9:30 AM EST - Wall Street Resources, Inc. Releases a Research Report on CTD Holdings, Inc.
Feb 21, 2012, 7:50 AM EST - CTD Holdings, Inc. Reports Record Revenues for the Third Quarter 2011
Nov 22, 2011, 8:00 AM EST - CTD Holdings, Inc. - NanoSonic Products Division Receives $44,625 Grant From USDA
Oct 27, 2011, 8:00 AM EDT - NanoSonic Products, Inc. Ribbon-Cutting Event a Smashing Success
Aug 1, 2011, 10:55 AM EDT - CTD Holdings, Inc. Smashes Quarterly Sales Record
Jul 20, 2011, 8:30 AM EDT - World's Only cGMP Pulse Drying Facility for the Production of Cyclodextrin Complexes Begins Operation in Alachua, Florida
Jul 13, 2011, 11:31 AM EDT - CTD Holdings, Inc. Reports Record 1st Quarter 2011 Sales
May 19, 2011, 3:45 PM EDT - New Independent Accounting Firm Positions CTD Holdings, Inc. for Continued Growth
Apr 27, 2011, 2:28 PM EDT - CTD Holdings, Inc. Reports Record 2010 Sales
Apr 5, 2011, 9:58 AM EDT - CTD Holdings, Inc. Closes on Credit Facility Package With SunState Federal Credit Union
Mar 22, 2011, 12:33 PM EDT - CTD Holdings, Inc. Adopts Revised Corporate Structure
Jan 31, 2011, 2:21 PM EST - CTD Holdings, Inc. Expands Investor Relations Program: Integrated In-House Investor Relations Program
Dec 14, 2010, 4:15 PM EST - CTD Holdings, Inc. Reorganizes Structure to Better Emphasize Branded Products, Trappsol® and Aquaplex®
Mar 8, 2010, 8:00 AM EST - CTD Holdings, Inc. Announces Profitable 3rd Quarter Results
Nov 18, 2009, 8:00 AM EST - ViStra Growth Partners to Begin Accepting Clients
Nov 17, 2009, 8:00 AM EST
